5 Key BioPharma Movers That Cannot Be Ignored
Bluebird Bio, Idera Pharmaceuticals and others stood out from other biotech stock with incredible gains or losses over the course of the past week.
All Work
Chris Lange
5 Companies That Absolutely Destroyed Shareholders This Past Week
Here are five companies that punished their shareholders this past week, a rough one for the broad markets.
Why Key Analyst Is Still Very Positive on First Data
Oppenheimer initiated coverage of First Data with an Outperform rating and a $20 price target.
More Tales of Caution in 3D Printing
Oppenheimer thinks that Stratasys has hit an earnings bottom, but investors still should remain cautious and vigilant.
How Key Analyst Views NXP Semiconductors After the Freescale Close
The new NXP Semiconductors is one of the best deleveraging/financial engineering stories in the industry, in Oppenheimer's view.
SEC Suspends Public Accountants Over Bad Audits
The U.S. Securities and Exchange Commission has suspended five accountants and two audit firms from practicing or appearing before the it.
November Retail Sales Heat Up a Little
The U.S. Census Bureau has released the retail sales report, which estimates U.S. retail and food services sales, for the month of November.
PPI Beats November Estimates
The seasonally adjusted Producer Price Index (PPI) increased more than expected in November.
Why Investors Are Disappointed in the Dow-DuPont Merger
After DuPont and Dow confirmed their merger of equals on Friday morning, investors reacted with incredible disappointment.
Banner Gears Up for Secondary Offering
Banner has filed with the U.S. Securities and Exchange Commission (SEC) regarding a secondary offering.
How Adobe Knocked Out Earnings
Adobe Systems reported its fiscal fourth-quarter financial results after the markets closed on Thursday.
Atlassian Skyrockets in IPO
When Atlassian entered the market late on Thursday morning, its shares went out well above the expected price range.
Blount Absolutely Soars on Acquisition Agreement
Blount International announced that it entered into a definitive agreement to be acquired by affiliates of American Securities and P2 Capital Partners, in an all-cash transaction valued at roughly $855 million.
Will LoJack Go for the Buyout Bid This Time? Is It Enough?
CalAmp has announced a bid to acquire LoJack in a transaction valued at approximately $113 million.
Yirendai Announces Pricing Terms for IPO
Yirendai is offering more than 7 million American depositary shares in an expected price range of $9 to $11 per ADS, in an IPO valued up to more than $82 million.
5 Key Tips and Tricks to Save Money This Holiday Season
24/7 Wall Street has compiled a list the top five tips and tricks that you can use to save money during this holiday season.
SoulCycle Readies for IPO
SoulCycle has amended its filing with the Securities and Exchange Commision (SEC) for its initial public offering (IPO).
CSRA Gears Up for Secondary Offering
The CSRA secondary offering of almost 25 million shares is valued at more than $696 million.
Cara Therapeutics Posts Strong Phase 2 Results
Cara Therapeutics saw its stock rise in Wednesday’s session on statistically significant Phase 2 results, but the delight of investors may be short lived.
Imports and Exports Remain Low in November
The cross-border price pressures continued to be negative, with import prices down 0.4% in November and export prices down 0.6%.